Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of KHN922 injection in advanced solid tumors
CTR20261200Phase 2Active
- Sponsor
- Chengdu Kanghong Pharmaceutical Group
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of KHN922 in Nonhematologic neoplasms, sponsored by Chengdu Kanghong Pharmaceutical Group. Started Apr 2026; status: active.
02
Drugs
KHN922
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20261200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261200.